NCNA NuCana PLC Company Short-Term Debt

Public company logo of NuCana Corp (NCNA)

NuCana plc (NCNA) focuses on developing advanced chemotherapeutic agents designed to overcome tumor treatment resistance. The company achieves cost optimization by engaging European CRO contractors for substance synthesis and testing. The market price confirmed by this chart, where the indicator stands at 0.00, complements data on the ProTide-based oncology ecosystem, which creates a protected patent perimeter around its protocols.

NCNA (NuCana plc) Company Short-Term Debts history from 07/04/2022 to 11/01/2026

Analytical breakdowns for NuCana PLC (NCNA)

- stock price and consensus target price:
Stock Price NuCana Corp|NCNA - Average Forecast Price
- market capitalization data:
Market Value NuCana plc|NCNA - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Book Value per Share NuCana|NCNA - Book Capitalization|Market Value to Book Value Ratio nucana.com|NCNA - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio NuCana plc|NCNA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity NuCana Corp|NCNA - Company Cumulative Debt|Debt to Book Capitalization Ratio NuCana plc|NCNA - Company Long-Term Indebtedness|Company Short-Term Debts NuCana|Quick Liquidity nucana.com
- net income and valuation multiples indicators:
NCNA - Company Net Income
Basic company analysis:NCNA - nucana.com
Flagship merchandise of NuCana Corp

When selecting defensive assets, the priority becomes minimizing liquidity risks, which for NuCana plc (NCNA) is ensured by the stability of its R&D core and the absence of talent shortages among leading biotechnologists. An analysis of the short-term debt load allows for an assessment of total liabilities maturing within one year, determining the business's ability to service current loans without compromising the development of anti-cancer drugs.

Direct competitors

Incyte - Company Short-Term Debts|Short-Term Debt Hutchison MediPharma|Nuvation Pharma (NUVB) - Company Short-Term Debt|Day One Biopharmaceuticals Inc - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts inhibrx.com|Company Short-Term Debt I-Mab (IMAB)|Company Short-Term Debt FENC (Fennec Pharma)|Heron Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Loans and Borrowings NVCT|CHRS - Company Short-Term Debt|Short-Term Debt corbuspharma.com|cardiffoncology.com (CRDF) - Company Short-Term Debt|Company Short-Term Indebtedness BYSI|BCAB (BioAtla Inc) - Company Short-Term Debts|Company Current Liabilities Lixte Biotechnology, Inc. (LIXT)|Company Short-Term Debt Citius Pharmaceuticals (CTXR)|CLRB - Short-Term Debt|Company Short-Term Debt BioLineRx BLRX|Can-Fite BioPharma Ltd - Company Short-Term Debt|APRE - Company Short-Term Debt|Short-Term Debt Kazia Therapeutics|SLXN: Company Short-Term Debts|Short-Term Indebtedness chimerix.com CMRX|Company Current Liabilities CYCC|Short-Term Debt G1 Pharma GTHX|Company Current Liabilities KRON (Kronos Bio Corp)|KTRA (Kintara Pharma) - Company Short-Term Loans and Borrowings|Oncternal Therapeutics - Company Current Liabilities|Amount of Current Liabilities PRTG (portagebiotech.com)